Comparison of blood glucose, HbA1c, and fructosamine is essential for understanding how diabetes is monitored and diagnosed across different clinical settings. Each test measures glycaemic control over a distinct time frame: blood glucose captures a real-time snapshot, fructosamine reflects the past two to three weeks, and HbA1c provides a two-to-three-month average. Knowing how these tests differ — and when each is most appropriate — helps patients and clinicians make informed decisions about diabetes management, treatment adjustments, and monitoring strategies within NHS practice.

How Blood Glucose, HbA1c and Fructosamine Measure Diabetes Control

Blood glucose gives an immediate reading in mmol/L, HbA1c reflects a two-to-three-month average of glycaemic control, and fructosamine reflects the past two to three weeks by measuring glycated serum proteins.

Managing diabetes effectively relies on accurate monitoring of blood sugar levels over different time frames. Three principal tests are used in clinical practice — blood glucose, HbA1c, and fructosamine — each offering a distinct window into how well blood sugar is being controlled.

Blood glucose measures the concentration of glucose in the blood at a single point in time, expressed in millimoles per litre (mmol/L). It can be measured as a fasting sample, a random sample, or as part of an oral glucose tolerance test (OGTT). It reflects what is happening metabolically right now, making it useful for immediate clinical decisions.

HbA1c (glycated haemoglobin) works on a different principle. Glucose in the bloodstream naturally binds to haemoglobin — the protein inside red blood cells — in a process called glycation. Because red blood cells survive for approximately 120 days, the HbA1c level reflects average blood glucose control over the preceding two to three months. In the UK, HbA1c is reported in mmol/mol (the IFCC unit); the NGSP percentage may sometimes appear in brackets on laboratory reports.

Importantly, HbA1c is not appropriate for diagnosing diabetes in certain situations, including pregnancy, children and young people, suspected type 1 diabetes, acute illness, and any condition that alters red blood cell turnover or haemoglobin structure. In these circumstances, plasma glucose measurements are used instead.

Fructosamine measures glycated serum proteins, predominantly albumin, which has a shorter lifespan of approximately 14–21 days. This means fructosamine reflects average blood glucose control over the preceding two to three weeks. It is expressed in micromoles per litre (µmol/L).

Together, these three tests provide complementary information — from the immediate snapshot of blood glucose to the medium-term picture offered by fructosamine and the longer-term overview provided by HbA1c.

Key Differences Between Each Test and What They Reveal

Blood glucose is a real-time measure, fructosamine reflects the past 2–3 weeks, and HbA1c reflects the past 2–3 months; each answers a different clinical question and is most useful when interpreted alongside the others.

Understanding the distinctions between these tests helps both patients and clinicians choose the most appropriate monitoring tool for a given clinical situation.

Blood glucose is highly dynamic. It fluctuates throughout the day in response to meals, physical activity, stress, illness, and medication. A single reading cannot reliably indicate overall diabetes control, but it is invaluable for detecting hypoglycaemia (low blood sugar) or hyperglycaemia (high blood sugar) in real time. Home blood glucose monitoring using a glucometer or continuous glucose monitoring (CGM) devices allows patients to track these fluctuations themselves.

HbA1c provides a stable, reproducible measure of long-term glycaemic control. NICE guidelines (NG28) recommend HbA1c as the primary tool for diagnosing type 2 diabetes in adults without the exclusions noted above (a level of 48 mmol/mol or above, confirmed on a second occasion in the absence of symptoms). It is also used to monitor treatment targets. NICE-recommended HbA1c targets vary according to individual circumstances and treatment:

• 48 mmol/mol (6.5%) is a commonly recommended target for many people with type 2 diabetes not at risk of hypoglycaemia

• 53 mmol/mol (7.0%) may be more appropriate for those on insulin, sulfonylureas, or other agents that carry a risk of hypoglycaemia

• Targets should always be individualised in discussion with your healthcare team

Because HbA1c reflects a two-to-three-month average, it is less sensitive to short-term changes in management.

Fructosamine bridges the gap between these two extremes. Its two-to-three-week window makes it particularly sensitive to recent changes in blood glucose control — for example, following a medication adjustment or dietary change.

Key differences at a glance:

• Blood glucose: immediate, real-time measurement

• Fructosamine: reflects the past 2–3 weeks

• HbA1c: reflects the past 2–3 months

Each test answers a different clinical question, and they are most powerful when interpreted together rather than in isolation.

When Each Test Is Used in NHS Clinical Practice

HbA1c is the cornerstone of diabetes monitoring in NHS primary care; blood glucose is used for real-time and diagnostic testing; fructosamine is reserved for situations where HbA1c is unreliable, such as haemoglobinopathies or recent transfusion.

In NHS clinical practice, the choice of test depends on the clinical context, the patient's individual circumstances, and the specific question being asked.

Blood glucose testing is used routinely in several settings. Fasting plasma glucose is used in the diagnosis of diabetes and impaired fasting glucose. The OGTT is used primarily for diagnosing gestational diabetes and impaired glucose tolerance; it is not routinely required for diagnosing type 2 diabetes in adults where HbA1c or fasting plasma glucose suffice. Point-of-care blood glucose testing is standard in hospital wards, emergency departments, and for patients self-monitoring at home.

HbA1c is the cornerstone of diabetes monitoring in primary care. It is used to:

• Diagnose type 2 diabetes in adults (where exclusions do not apply)

• Identify non-diabetic hyperglycaemia (HbA1c 42–47 mmol/mol)

• Set and review individual glycaemic targets

• Monitor the effectiveness of lifestyle changes, oral medications, or insulin therapy

• Inform assessment of long-term glycaemic exposure linked to microvascular and macrovascular risk (note: formal cardiovascular risk assessment in the UK uses validated tools such as QRISK, not HbA1c alone)

NICE (NG28) recommends HbA1c be checked every three to six months when treatment is being adjusted, and every six months once stable.

CGM is now recommended by NICE (NG17) for all adults with type 1 diabetes as an alternative to finger-prick blood glucose monitoring. HbA1c is still used for periodic review, but CGM metrics such as time-in-range provide additional information that HbA1c alone cannot capture.

Fructosamine is less commonly requested in routine NHS practice but has specific clinical indications. It is particularly useful when HbA1c results are unreliable or uninterpretable — for example, in patients with haemolytic anaemia, haemoglobinopathies (such as sickle cell disease or thalassaemia), or following a recent blood transfusion. It may also be considered in specialist or exceptional circumstances where a short-term assessment of glycaemic control is needed and HbA1c is not valid. It is important to note that in pregnancy and gestational diabetes, the primary monitoring approach recommended by NICE (NG3) is self-monitoring of capillary blood glucose or CGM — fructosamine is not routinely recommended in this setting. Clinicians may also use fructosamine to assess the impact of a recent change in diabetes treatment within a matter of weeks.

Accuracy, Limitations and Factors That Affect Results

HbA1c is falsely lowered by haemolytic anaemia and recent transfusion, and falsely elevated by iron or B12 deficiency; fructosamine is unreliable when serum albumin is low, as in nephrotic syndrome or liver cirrhosis.

No single test is perfect, and each has recognised limitations that clinicians must account for when interpreting results.

Blood glucose is highly susceptible to acute variables. Stress, recent food intake, illness, and even the timing of the test can significantly alter the result. A single elevated reading does not confirm diabetes, and a normal fasting glucose does not exclude impaired glucose tolerance. Technique matters too — improper calibration of home glucometers or contamination of the finger with food residue can produce inaccurate readings.

HbA1c is affected by conditions that alter red blood cell turnover or haemoglobin structure. RCPath and ACB guidance highlights the following:

• Falsely low HbA1c: haemolytic anaemia, recent blood transfusion, and conditions causing increased red cell turnover

• Falsely elevated HbA1c: iron deficiency anaemia (before treatment); vitamin B12 deficiency; splenectomy. Note that after starting iron therapy, HbA1c may fall independently of any change in glycaemia during the recovery phase — results should therefore be interpreted with caution

• Haemoglobinopathies (e.g., HbS, HbC, HbE) can interfere with certain HbA1c assay methods; UK laboratories typically use IFCC-aligned methods with variant detection, but results should still be interpreted carefully in these populations

Where HbA1c is unreliable due to any of the above, RCPath/ACB and IFCC guidance recommends considering an alternative measure such as fructosamine or relying on plasma glucose testing.

Fructosamine is affected by conditions that alter serum protein levels. Because it primarily measures glycated albumin, any condition causing low albumin — such as nephrotic syndrome, liver cirrhosis, or malnutrition — will produce a falsely low fructosamine result. Elevated immunoglobulins (as seen in some inflammatory or haematological conditions) may also interfere with the assay. Fructosamine lacks the extensive standardisation and reference range data that HbA1c benefits from, making cross-laboratory comparisons less straightforward. Results should always be interpreted in clinical context and alongside the laboratory-specific reference range.

Which Test Is Most Appropriate for Your Situation

HbA1c is preferred for most adults with type 2 diabetes; fructosamine is most appropriate when HbA1c is unreliable; plasma glucose is used when HbA1c is contraindicated for diagnosis.

Selecting the most appropriate test requires careful consideration of the individual patient's clinical circumstances, the question being asked, and any factors that might compromise the reliability of a particular assay.

For most people with type 2 diabetes managed in primary care, HbA1c remains the preferred test for monitoring long-term glycaemic control. It is well-validated, widely standardised across NHS laboratories, and directly linked to evidence-based treatment targets in NICE guidelines (NG28). It is the preferred test for diagnosis and routine review in adults, provided none of the following exclusions apply.

HbA1c should not be used for diagnosis in:

• Pregnancy (including gestational diabetes)

• Children and young people

• Suspected type 1 diabetes

• Acute illness or recent onset of symptoms suggestive of diabetes

• Conditions affecting red blood cell turnover or haemoglobin structure (e.g., haemolytic anaemia, haemoglobinopathies, recent transfusion)

In these situations, plasma glucose measurements (fasting, random, or OGTT) are used instead.

For people with type 1 diabetes, CGM is now recommended by NICE (NG17) for all adults as the primary monitoring approach. HbA1c is still used for periodic review, but CGM metrics such as time-in-range provide additional nuance.

Fructosamine is most appropriate in the following situations:

• Patients with haemoglobinopathies or haemolytic conditions where HbA1c is unreliable

• Patients who have recently received a blood transfusion

• Evaluating the short-term response to a recent change in medication or diet

• Specialist or exceptional circumstances where a short-interval glycaemic assessment is needed and HbA1c is not valid

In pregnancy and gestational diabetes, the primary monitoring approach per NICE (NG3) is self-monitoring of capillary blood glucose or CGM; fructosamine is not routinely recommended in this setting.

It is worth noting that fructosamine has not been validated against cardiovascular outcome data in the way that HbA1c has been in large clinical trials, which limits its use as a standalone long-term monitoring tool. The decision about which test to use should always be guided by your GP, diabetes specialist nurse, or endocrinologist, taking into account your full medical history.

Understanding Your Results and Next Steps with Your GP

An HbA1c of 48 mmol/mol or above confirms type 2 diabetes in eligible adults; fasting plasma glucose of 7.0 mmol/L or above on two occasions also indicates diabetes; results outside normal ranges should be discussed with your GP.

Receiving a diabetes-related blood test result can feel confusing, particularly when different tests are used at different appointments. Understanding what each result means — and what action it may prompt — is an important part of managing your health.

UK diagnostic and reference ranges:

Fasting plasma glucose (WHO/NICE-aligned):

• Below 6.1 mmol/L: normal

• 6.1–6.9 mmol/L: impaired fasting glucose (IFG)

• 7.0 mmol/L or above on two occasions (or once with symptoms): indicates diabetes

Random plasma glucose:

• 11.1 mmol/L or above in the presence of symptoms of diabetes indicates diabetes

2-hour OGTT plasma glucose:

• Below 7.8 mmol/L: normal glucose tolerance

• 7.8–11.0 mmol/L: impaired glucose tolerance (IGT)

• 11.1 mmol/L or above: indicates diabetes

HbA1c:

• Below 42 mmol/mol: normal

• 42–47 mmol/mol: non-diabetic hyperglycaemia (sometimes referred to as prediabetes; the preferred UK term is non-diabetic hyperglycaemia)

• 48 mmol/mol or above on two occasions (or once with symptoms): confirms type 2 diabetes in adults where exclusions do not apply

Fructosamine:

• Normal reference ranges vary by laboratory but are typically 200–285 µmol/L in non-diabetic adults; your GP or laboratory report will indicate whether your result is within the expected range for your situation

If your results are outside the normal range, your GP will discuss what this means in the context of your overall health. A single abnormal result does not always require immediate treatment — lifestyle factors such as diet, physical activity, weight management, and smoking cessation are often the first line of intervention for non-diabetic hyperglycaemia.

Contact your GP promptly if you experience:

• Symptoms of hypoglycaemia (shakiness, sweating, confusion, palpitations)

• Persistent thirst, frequent urination, or unexplained weight loss

• Blood glucose readings consistently above your agreed target

• Any concerns about your medication or monitoring equipment

Seek urgent medical attention (call 999 or go to A&E) if you or someone with diabetes develops:

• Vomiting, severe abdominal pain, deep or laboured breathing, confusion, drowsiness, or a positive ketone reading — these may be signs of diabetic ketoacidosis (DKA) or hyperosmolar hyperglycaemic state (HHS), both of which require immediate medical care

Regular review appointments are essential. Diabetes management is not static — targets and tests may need to be adjusted as your circumstances change. Open communication with your healthcare team ensures that the most appropriate monitoring strategy is always in place for you.

Frequently Asked Questions